Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization

Viral Immunology

Volumn 22, Issue 3, 2009, Pages 195-204

  Mustafa, Waleed ^a   Maciag, Paulo Cesar ^a   Pan, Zhen Kun ^a   Weaver, Jessica R ^a   Xiao, Yuhong ^a   Isaacs, Stuart N ^a   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; GAMMA INTERFERON; LISTERIOLYSIN O; BACTERIAL TOXIN; CAPSID PROTEIN; HEAT SHOCK PROTEIN; HEMOLYSIN; HLYA PROTEIN, LISTERIA MONOCYTOGENES; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; HYBRID PROTEIN; ONCOPROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; INTERFERON PRODUCTION; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; PEYER PATCH; SPLEEN; UTERINE CERVIX; UTERUS; VACCINIA VIRUS; VIRUS TITRATION; ACTIVE IMMUNIZATION; ANIMAL; BIOSYNTHESIS; CELLULAR IMMUNITY; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; MUCOSAL IMMUNITY; ORAL DRUG ADMINISTRATION; SECRETION; VIROLOGY; VIRUS INFECTION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; LISTERIA MONOCYTOGENES; MIRIDAE; MUS; VACCINIA VIRUS;

ADMINISTRATION, ORAL; ANIMALS; BACTERIAL TOXINS; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CERVIX UTERI; FEMALE; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOTHERAPY, ACTIVE; LISTERIA MONOCYTOGENES; MICE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS;

EID: 67049119147     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2008.0071     Document Type: Article

References (56)

1. Ho GY, Burk RD, Klein S, et al.: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-1371.
2. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al.: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-25. (Pubitemid 29304297)
3. Wallin KL, Wiklund F, Angstrom T, et al.: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999; 341:1633-1638.
4. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, and Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265. (Pubitemid 34293391)
5. Zhou J, Sun XY, Davies H, Crawford LV, Park D, and Frazer IH: Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology 1992;189:592-1529
6. Gissmann L, Osen W, Muller M, and Jochmus I: Therapeutic vaccines for human papillomaviruses. Intervirology 2001;44: 167-175.
7. Schiller JT and Lowy DR: Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2001;28:50-54.
8. Schiller JT and Davies P: Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2:343-347. (Pubitemid 39490104)
9. Harper DM, Franco EL, Wheeler C, et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial: Lancet 2004;364: 1757-1765.
10. Lowy DR and Schiller JT: Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-1173.
11. Villa LL, Costa RL, Petta CA, et al.: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-1466.
12. Rose RC, White WI, Li M, Suzich JA, Lane C, and Garcea RL: Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998;72:6151-6154. (Pubitemid 28283406)
13. Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, Garcea RL, and Schlegel R: Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 2001;759:7848-7853. (Pubitemid 32743655)
14. Ohlschlager P, Osen W, Dell K, et al.: Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003;77:4635-4645. (Pubitemid 36402813)
15. Holmgren J and Czerkinsky C: Mucosal immunity and vaccines. Nat Med 2005;11:(4 Suppl)S45-S53.
16. Neutra MR and Kozlowski PA: Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6:148-158.
17. Aziz MA, Midha S, Waheed SM, and Bhatnagar R: Oral vaccines: new needs, new possibilities. Bioessays 2007;29: 591-604. (Pubitemid 46903947)
18. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, and Nardelli-Haefliger D: Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998; 72:8220-8229. (Pubitemid 28421819)
19. Dupuy C, Buzoni-Gatel D, Touze A, Bout D, and Coursaget P: Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999;73:9063-9071. (Pubitemid 29487059)
20. Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, and Williamson AL: Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virusneutralizing antibodies. Vaccine 1999;179:2129-2135. (Pubitemid 29197279)
21. Gerber S, Lane C, Brown DM, et al.: Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 2001;75:4752-4760. (Pubitemid 32381518)
22. Mestecky J, Kutteh WH, and Jackson S: Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus. AIDS Res Hum Retroviruses 1994;10(Suppl 2):S11-S20. (Pubitemid 24375432)
23. Kozlowski PA, Cu-Uvin S, Neutra MR, and Flanigan TP: Mucosal vaccination strategies for women. J Infect Dis 1999;179:(Suppl 3)S493-S498.
24. Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, and De Grandi P: Mucosal but not parenteral immunization with purified human papillomavirus type 16 viruslike particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol 1999;73:9609-9613. (Pubitemid 29487118)
25. Gedde MM, Higgins DE, Tilney LG, and Portnoy DA: Role of listeriolysin in cell-to-cell spread of Listeria monocytogenes. Infect Immun 2000;68:999-1003.
26. Pamer EG, Sijts AJ, Villanueva MS, Busch DH, and Vijh S: MHC class I antigen processing of Listeria monocytogenes proteins: implications for dominant and subdominant CTL responses. Immunol Rev 1997;158:129-136.
27. Ikonomidis G, Portnoy DA, Gerhard W, and Paterson Y: Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines. Vaccine 1997;15:433-440. (Pubitemid 27156161)
28. Boyer JD, Robinson TM, Maciag PC, et al.: DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology 2005;333: 88-101.
29. Boyer JD, Maciag PC, Parkinson R, Wu L, Lewis MG, Weiner DB, and Paterson Y: Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239. Vaccine 2006;24:4498-4502. (Pubitemid 43776764)
30. Neeson P, Boyer J, Kumar S, et al.: A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response with high levels of α4β7 integrin and effector memory phenotype. Virology 2006;354: 299-315. (Pubitemid 44559651)
31. Peters C, Peng X, Douven D, Pan ZK, and Paterson, Y: The induction of HIV-Gag specific CD8 + T cells in the spleen and GALT by parenteral or mucosal immunization using recombinant Listeria monocytogenes-HIV-Gag. J Immunol 2003;170:5176-5187. (Pubitemid 36554750)
32. Pan, ZK, Ikonomidis G, Lazenby A, Pardoll D, and Paterson Y: A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med 1995;1:471-477.
33. Pan ZK, Weiskirch LM, and Paterson Y: Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res 1999;59:5264-5269.
34. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, and Paterson Y: Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001;167:6471-6479. (Pubitemid 33081581)
35. Souders NC, Sewell DA, Pan ZK, et al.: Listeria-based vaccines can overcome tolerance by expanding low avidity CD8 + T cells capable of killing a solid tumor in a transgenic mouse model of cancer. Cancer Immunity 2007;7:2.
36. Singh R, Dominiecki ME, Jaffee EM, and Paterson Y: Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol 2005;175:3663-3673. (Pubitemid 41292026)
37. Touze A, Mahe D, El Mehdaoui S, et al.: The nine C-terminal amino acids of the major capsid protein of the human papillomavirus type 16 are essential to DNA binding and gene transfer capacity. FEMS Microbiol Lett 2000;189:121-127. (Pubitemid 30456258)
38. Laure P, Chow MY, Loessner MJ, Portnoy DA, and Calendar R: Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J Bacteriol 2002;184:4177-4186.
39. Verch T, Pan ZK, and Paterson Y: Listeria monocytogenesbased antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect Immun 2004;72:6418-6425. (Pubitemid 39425422)
40. Marais D, Passmore JA, Maclean J, Rose R, and Williamson AL: A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cellmediated immunity against HPV virus-like particles. J Gen Virol 1999;80:2471-2475 (Pubitemid 29408377)
41. Chakrabarti S, Sisler JR, and Moss B: Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997;23:1094-1097. (Pubitemid 27523268)
42. Jiang JQ, Patrick A, Moss RB, and Rosenthal KL: CD8+T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J Virol 2005;79:393-400. (Pubitemid 39648392)
43. North RJ, Berche PA, and Newborg MF: Immunologic consequences of antibiotic-induced abridgement of bacterial infection: effect on generation and loss of protective T cells and level of immunologic memory. J Immunol 1981;127:342-346.
44. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, and Estes MK: Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 2001;75: 9713-9722.
45. Shi W, Liu J, Huang Y, and Qiao L: Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 2001;75:10139-10148. (Pubitemid 32948044)
46. Niikura M, Takamura S, Kim G, et al.: Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 2002;293:273-280. (Pubitemid 34928848)
47. Galen JE, and Levine, MM: Can a "flawless" live vector vaccine strain be engineered? Trends Microbiol 2001;9:372-376.
48. Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, and Nardelli-Haefliger D: Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 2001;279: 354-360. (Pubitemid 34161025)
49. Fraillery D, Baud D, Pang SY, et al: Salmonella enterica serovar typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 2007;14:1285-1295. (Pubitemid 350012970)
50. Sasagawa T, Tani M, Basha W, et al.: A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res 2005;110:81-90. (Pubitemid 40544549)
51. Hu J, Cladel NM, Budgeon LR, Reed CA, Pickel MD, and Christensen ND: Protective cell-mediated immunity by DNA vaccination against papillomavirus L1 capsid protein in the cottontail rabbit papillomavirus model. Viral Immunol 2006;19:492-507. (Pubitemid 44735061)
52. Govan VA, Rybicki EP, and Williamson AL: Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas. Virol J 2008;5:45.
53. Hildesheim A, Herrero R, Wacholder S, et al., and the Costa Rican HPV Vaccine Trial Group: Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-753.
54. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, and Broker TR: Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992;23: 117-128.
55. Choo KB, Pan CC, and Han SH: Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 1987;161:259-261.
56. Vousden KH, Doniger J, DiPaolo JA, and Lowy DR: The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res 1988;3:167-175. (Pubitemid 19085034)